Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maxcyte Inc (NQ: MXCT )

3.550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Maxcyte Inc

< Previous 1 2 3 4 5 Next >
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
MaxCyte Inc (NASDAQ: MXCT) has signed a  
Via Benzinga
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Recap: MaxCyte Q2 Earnings
  MaxCyte (NASDAQ:MXCT) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings MaxCyte reported in-line EPS of... 
Via Benzinga
A Preview Of MaxCyte's Earnings
  MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will... 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
MaxCyte's Return On Capital Employed Insights
Benzinga Pro data, MaxCyte (NASDAQ:MXCT) reported Q4 sales of $10.15 million. Earnings fell to a loss of $4.87 million, resulting in a 81.85% decrease from last quarter. MaxCyte... 
Via Benzinga
Earnings Scheduled For March 22, 2022
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (... 
Via Benzinga
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
11 Health Care Stocks Moving In Monday's Intraday Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares rose 35.6% to $2.17 during Monday's regular session. The current volume of 5.6 million shares is 531.8% of Aridis... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA 
Via Benzinga
MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript
MXCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
91 Biggest Movers From Yesterday
Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! We're starting off the trading week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR... 
Via Benzinga
18 Stocks Moving in Friday's Pre-Market Session
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well
The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO)... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 30.07% to $3.59 during Monday's pre-market session. The market value of their outstanding shares is at $137.3... 
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For September 13, 2021
Companies Reporting Before The Bell • Optical Cable (NASDAQ:OCC) is expected to report earnings for its third quarter. • NAPCO Security (NASDAQ:NSSC) is estimated... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.